BILBF yields 370.37% · JNJ yields 2.14%● Live data
📍 BILBF pulled ahead of the other in Year 1
Combined, BILBF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BILBF + JNJ for your $10,000?
Kinovo plc, through its subsidiaries, provides gas heating, electrical, and general building services to housing associations and local authorities, public buildings, industrial and commercial, and education and private sectors in the United Kingdom. The company operates through Mechanical Services, Building Services, and Electrical Services segments. It offers safety and regulatory compliance services for electric, gas, access control systems, ventilation and fire alarm systems, and water hygiene services; and home and community regeneration services, including new home construction, brownfield site regeneration, vacant building conversion, habitual spaces improvement, building maintenance, reactive repairs and maintenance, create greener buildings, disabled adaption work, unused space reutilization, and kitchen and bathroom installations. The company also delivers and installs photovoltaic solar microgeneration systems, ground and air source heat pumps, electric vehicle charging, air source heat pumps, energy boilers and lightings, and energy management systems. In addition, it provides meter connections and central heating installation solutions; window installations, and painting and decorating services; servicing, maintenance, emergency call out, and rewiring solutions. The company was formerly known as Bilby Plc and changed its name to Kinovo plc in June 2021. Kinovo plc was incorporated in 2014 and is based in London, the United Kingdom.
Full BILBF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.